Paulo Jacob Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paulo Jacob Silva has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Stellacci
Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL)
4 shared publications - Anaïs Hubart
Department of Microbiology, Immunology and Transplantation, Rega Institute, Virus-Host Interactions & Therapeutic Approaches (VITA) Research Group, KU Leuven, Leuven, Belgium
2 shared publications Charlotte Deloizy
INRAE, UVSQ, UMR892 VIM, Université Paris-Saclay, 78350 Jouy-en-Josas, France
2 shared publicationsClémentine Prompt
INRAE, UVSQ, UMR892 VIM, Université Paris-Saclay, 78350 Jouy-en-Josas, France
2 shared publications- Gregory Mathez
Institute of Microbiology, University Hospital of Lausanne, University of Lausanne, 1011 Lausanne, Switzerland
2 shared publications - Joana Rocha-Pereira
Department of Microbiology, Immunology and Transplantation, Rega Institute, Virus-Host Interactions & Therapeutic Approaches (VITA) Research Group, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 16 September 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 10 (11) , 3061-3071
Proline stabilizes amphiphilic gold nanoparticles via hydrophobic interactions
Colloidal dispersions are key in many fields of science and technology. Recently, we have shown that small molecules can stabilize dispersions of nanoscale objects, such as proteins and nanoparticles by screening their net attractive interactions. This new effect is essentially the opposite of the well-known salt screening of electrostatic interaction. Here we show that small molecule stabilization of nanoparticles is a phenomenon strongly linked to the hydrophobic content of the particles as well as to the strength of their hydrophobic attraction. We compare the effect of proline on gold nanoparticles coated with 11-mercaptoundecane sulfonate (MUS) at varying percentages of the hydrophobic ligand octanethiol (OT). We show that the larger the percentage of OT, the larger the proline stabilization effect is. We also compare the effect of proline on water dispersions of nanoparticles with that on heavy water dispersions. In the latter, the hydrophobic effect plays a bigger role. We find that in D2O, proline stabilization is larger. We also compare the effect of proline on the same MUS:OT gold nanoparticles before and after an annealing process that is known to render the particle more hydrophilic. Proline is more effective on the particles before annealing. Finally, we study the effect of proline on non-aggregating allMUS nanoparticles. We find that proline stabilization of these particles is mainly due to a reduction in the long-range attraction coefficient. Overall, we show that proline stabilizes nanoparticle dispersions more effectively as the hydrophobic attraction between nanoparticles increases.
- 16 September 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 10 (11) , 3061-3071
Open AccessProline stabilizes amphiphilic gold nanoparticles via hydrophobic interactions
Colloidal dispersions are key in many fields of science and technology. Recently, we have shown that small molecules can stabilize dispersions of nanoscale objects, such as proteins and nanoparticles by screening their net attractive interactions. This new effect is essentially the opposite of the well-known salt screening of electrostatic interaction. Here we show that small molecule stabilization of nanoparticles is a phenomenon strongly linked to the hydrophobic content of the particles as well as to the strength of their hydrophobic attraction. We compare the effect of proline on gold nanoparticles coated with 11-mercaptoundecane sulfonate (MUS) at varying percentages of the hydrophobic ligand octanethiol (OT). We show that the larger the percentage of OT, the larger the proline stabilization effect is. We also compare the effect of proline on water dispersions of nanoparticles with that on heavy water dispersions. In the latter, the hydrophobic effect plays a bigger role. We find that in D2O, proline stabilization is larger. We also compare the effect of proline on the same MUS:OT gold nanoparticles before and after an annealing process that is known to render the particle more hydrophilic. Proline is more effective on the particles before annealing. Finally, we study the effect of proline on non-aggregating allMUS nanoparticles. We find that proline stabilization of these particles is mainly due to a reduction in the long-range attraction coefficient. Overall, we show that proline stabilizes nanoparticle dispersions more effectively as the hydrophobic attraction between nanoparticles increases.
- Open Access
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadv9311
A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo
Respiratory viruses can cause severe infections, often leading to hospitalization or death, and pose a major pandemic threat. No broad-spectrum antiviral is currently available. However, most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized a modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, the compound is active against avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad-spectrum activity in ex vivo models of respiratory tissues and in vivo against respiratory syncytial virus and influenza virus, using prophylactic and therapeutic strategies. These findings contribute to the development of future treatments and preventive measures for respiratory viral infections.
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadv9311
Open AccessA pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo
Respiratory viruses can cause severe infections, often leading to hospitalization or death, and pose a major pandemic threat. No broad-spectrum antiviral is currently available. However, most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized a modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, the compound is active against avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad-spectrum activity in ex vivo models of respiratory tissues and in vivo against respiratory syncytial virus and influenza virus, using prophylactic and therapeutic strategies. These findings contribute to the development of future treatments and preventive measures for respiratory viral infections.
- Open Access
- 3 May 2025
- Published by Elsevier in Antiviral Research
- Vol. 239, 106174
Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models
- 3 May 2025
- Published by Elsevier in Antiviral Research
- Vol. 239, 106174
Open AccessInfluenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models
- Open Access
A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo
Respiratory viruses can cause severe infections, including bronchiolitis and pneumonia, often leading to hospitalization or death. Due to their ease of transmission, they are also scrutinized for their pandemic potential. No broad-spectrum antiviral is currently available. However most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized and characterized a unique modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This novel compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, SARS-CoV-2. Additionally, the compound is active against different avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad- spectrum activity in ex vivo models of respiratory tissues and in vivo experiments against RSV and Influenza virus, using both prophylactic and therapeutic strategies. These findings represent a significant step forward in the development of future treatments and preventive measures for respiratory viral infections. Significance Statement Following the SARS-CoV-2 pandemic, Influenza A H5N1 has become widespread in poultry and has already begun to spill over into mammals, posing a potential risk for the next pandemic. Indeed, respiratory viruses represent a major threat for future global health crises. Unfortunately, there is a significant lack of broad-spectrum antivirals available for such scenarios. To address this gap, our study developed a single molecule with the capacity to inhibit a wide range of clinically relevant human respiratory viruses including avian strains of influenza virus. This antiviral demonstrated verified efficacy not only in cellular systems but also in human-derived respiratory tissues and animal models.
Open AccessA pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo
Respiratory viruses can cause severe infections, including bronchiolitis and pneumonia, often leading to hospitalization or death. Due to their ease of transmission, they are also scrutinized for their pandemic potential. No broad-spectrum antiviral is currently available. However most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized and characterized a unique modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This novel compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, SARS-CoV-2. Additionally, the compound is active against different avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad- spectrum activity in ex vivo models of respiratory tissues and in vivo experiments against RSV and Influenza virus, using both prophylactic and therapeutic strategies. These findings represent a significant step forward in the development of future treatments and preventive measures for respiratory viral infections. Significance Statement Following the SARS-CoV-2 pandemic, Influenza A H5N1 has become widespread in poultry and has already begun to spill over into mammals, posing a potential risk for the next pandemic. Indeed, respiratory viruses represent a major threat for future global health crises. Unfortunately, there is a significant lack of broad-spectrum antivirals available for such scenarios. To address this gap, our study developed a single molecule with the capacity to inhibit a wide range of clinically relevant human respiratory viruses including avian strains of influenza virus. This antiviral demonstrated verified efficacy not only in cellular systems but also in human-derived respiratory tissues and animal models.